58 / 116
Terms represent groupings of similar or related adverse events
.
BCC=basal cell carcinoma; BRAFi=BRAF inhibitor; COMBO450=encorafenib 450 mg QD + binimetinib 45 mg BID; CuSCC=cutaneous squamous cell carcinoma;
ENCO300=encorafenib 300 mg QD; LVD=left ventricular dysfunction; MEKi=MEK inhibitor; VEM=vemurafenib 960 mg BID.
Rash Serous
retinopathy
PyrexiaTransaminases
increased
Skin
papilloma
LVD Photo-
sensitivity
CuSCC Dermatitis
acneiform
BCC Increased
bilirubin
0
10
20
30
40
50
60
Patient (%)
COMBO450 Updated analysis
ENCO300 Updated analysis
VEM Updated analysis
COMBO450 Initial analysis
ENCO300 Initial analysis
VEM Initial analysis
Reinhard Dummer
“Toxicidad agrupada”
En general…
Menos pirexia y menos fotosensibilidad
y más HTA, transaminitis y elevación
CK